FTC and seven state attorneys general asked a federal judge to hold Martin Shkreli in contempt for allegedly breaking his 2022 lifetime pharma ban. The filing treats his livestreamed commentary on the industry as a breach alongside his trading.
Perspective Coverage
5 publishers
- Builder
- Builder 5%
- Operator
- Operator 49%
- Investor
- Investor 46%
Reality
- Evidence55
- Adoption
- Insufficient
- Hype gap+8
- Incentives
- Insufficient
- Confidence72
Hanmi's Eppe is due this month at 129,800 won wholesale for four weeks, against about 210,000 to 270,000 won for Wegovy and Mounjaro. At the 299,200 won maintenance dose, Seoul Economic Daily puts the gap at 17% to 19%.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+30
- Incentives
- Insufficient
- Confidence55
Exponential View says GLP-1 sales reached $76 billion in 2025, ahead of its own $63 billion estimate for generative AI. The $13 billion lead rests on that estimate, and the retention studies the piece cites show heavy attrition.
Reality
- Evidence45
- Adoption11
- Hype gap+20
- Incentives40
- Confidence50
Korea's regulator approved Hanmi Pharmaceutical's efpeglenatide, the first homegrown GLP-1 obesity drug, after patients lost 9.02% of body weight in 40 weeks. That is less than Wegovy and Mounjaro showed in longer trials, so Hanmi's case rests on milder side effects and a price for long-term patients that it has not yet set.
Reality
- Evidence60
- Adoption8
- Hype gap+15
- Incentives60
- Confidence58
Hanmi Pharmaceutical's Eppe, Korea's first home-grown GLP-1 obesity drug, is approved and expected to launch at about half Wegovy's 200,000-won-plus price. Its trial weight loss trails both incumbents, so the launch price will set how much of a Mounjaro-dominated market it can reach.
Reality
- Evidence55
- Adoption8
- Hype gap+10
- Incentives40
- Confidence50
Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+25
- Incentives
- Insufficient
- Confidence40